ArticlePLoS computational biology2025
Block sparse Bayes-based fuzzy system for RNA N6-methyladenosine sites prediction.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
N6-methyladenosine (m6A) can significantly affect RNA expression, gene regulation, and determination of cell fate. As a common and abundant post-transcriptional modification (PTM) of RNA, m6A is also closely associated with the occurrence of numerous diseases. Thus, identifying the m6A modification site in the RNA sequence is a prerequisite for related research. High-throughput sequencing technology has high requirements and low cost performance. Computational methods have made encouraging progress in site prediction. However, most models only consider the effects of different species, ignoring the simultaneous exploration of RNA modifications in different tissues within the same species. We develop and validate a fuzzy system based on Block Sparse Bayesian Learning (BSBL), named BSBL-TSK-FS, which is a powerful sequence-level m6A prediction model. We introduce a Bayesian method that provides a posterior probability output to produce more sparse solutions so that the model has higher accuracy. The model classifies the m6A sites in several tissues of mouse, human, and rat. Under the five-fold cross-validation method (5-CV), the precision of the BSBL-TSK-FS model is 0.84∼0.95. The accuracy of our model improves by 9.4% over the existing SOTA predictors. BSBL-TSK-FS achieves superior performance over current SOTA methods. Finally, in order to verify the generalizability of the model, we carry out cross-species tests, and the results prove the robustness and adaptability of the model. An accurate and reliable sequence modification prediction model is developed to better understand the complex landscape of methylation modification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.